科学图书馆
-
Impact of bleeding during dual antiplatelet therapy in patients with coronary artery diseaseY-C Tung, C-T Kuo, C-J Chang et al. -
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)Kim BK, Hong MK, RESET Investigators.
-
Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral AnticoagulationC Genz, RC Braun-Dullaeus.
-
Ticagrelor With or Without Aspirin After Complex PCIG Dangas, U Baber, R Mehran et al.
-
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of theKedhi E, Fabris E, van der Ent M et al.
-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al.
-
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary InterventionDJ Angiolillo, U Baber, R Mehran et al.
-
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary InterventionJD McClure, JC Ramsay , C Berry et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
